{
  "docId": "019de071-4e1f-74a8-b040-3577ed32c01f",
  "docSlug": "716a1960d23114ac9a8076dbc94bca80",
  "documentTitle": "Tenaya Therapeutics | IPO Presentation Deck | 36 slides",
  "authorId": "tenaya-therapeutics",
  "authorName": "Tenaya Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7843866,
  "pageNumber": 19,
  "pageCount": 36,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide uses a two-column layout to contrast past achievements (Progress) with future goals (Next Steps).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-4e1f-74a8-b040-3577ed32c01f/19",
  "deckHref": "/decks/019de071-4e1f-74a8-b040-3577ed32c01f",
  "deckJsonHref": "/decks/019de071-4e1f-74a8-b040-3577ed32c01f.json",
  "deckAnchorHref": "/decks/019de071-4e1f-74a8-b040-3577ed32c01f#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.28,
        "x": 0.35,
        "y": 0.22
      },
      "kind": "list",
      "text": "US PTO Notice of Allowance supporting TN-201 IP; No unexpected safety signals; Manufacturing process locked (at 200L scale); Feedback from multiple regulatory agencies; Orphan Drug Designation; Positive engagement with KOLs & patient adv orgs",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9af04567-7b27-43ff-971e-68c72b3ad4db",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.03,
        "y": 0.22
      },
      "kind": "list",
      "text": "Significant and durable reversal out to 15 months; Survival benefit; Dose-dependent effect at clinically relevant doses; Differentiation vs data with other gene therapy constructs",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b251d603-6471-4b3c-b823-373debb16801",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.3,
        "x": 0.66,
        "y": 0.22
      },
      "kind": "list",
      "text": "Initiated IND-enabling studies (2021); Plan to initiate global natural history study (2021); Expect to file IND (2022)",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aea38066-4188-49a7-92d1-1a8dbc2ca928",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.7,
        "x": 0.03,
        "y": 0.09
      },
      "kind": "title",
      "text": "TN-201 is in IND-Enabling Studies with Several Important Upcoming Milestones",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d6a21cfe-1ae0-4da6-a698-bbfc6d689f8a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "MYBPC3 Gene Therapy Program",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "be06f06c-bb65-481a-b793-2de9065117f2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Monroe's Motivated Sequence",
      "slug": "monroes-motivated-sequence",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "ff3fa11e-541e-40e9-8a3f-3f1f28696a0f",
      "evidence": "list/bullet: US PTO Notice of Allowance supporting TN-201 IP; No unexpected safety signals; Manufacturing process locked (at 200L scale); Feedback from multiple regulatory agencies; Orphan Drug Designation; Positive enga",
      "confidence": 0.5
    }
  ],
  "frameworks": [
    {
      "name": "list-presentation",
      "slug": null,
      "matchId": "d004d1aa-a65b-4f67-a4aa-2b0f793d171b",
      "evidence": "The slide uses a structured list format to communicate progress and milestones.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 19,
      "from": 19,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "c3aa468e-d3bf-439f-a047-8a199e40d334",
      "evidence": "The 'TN-201 is in IND-Enabling Studies with Several Important Upcoming Milestones' slide",
      "position": 2,
      "objective": "Highlighting quick wins and big bets in the pipeline",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}